Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology

Inclusion Criteria: * Patients of more than 18 years of age * Patients presenting with anemia following chemotherapy * Patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy \-- The patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle) * Patients eligible for epoetin alfa biosimilar treatment Exclusion Criteria: * Patients are not receiving chemotherapy * Patients already included in an epoetin zeta trial * Patients presenting with a contraindication to epoetin zeta * Patients presenting with hypersensitivity to the active principle or any of the excipients * Patient with erythroblastopenia or acquired pure red cell aplasia (APRCA) * Patient with uncontrollable arterial hypertension * Patients who cannot receive adequate prophylaxis by antithrombotic agents